Patient achieves remission after experimental off-the-shelf cancer vaccine

After a massive liver tumor was removed, the patient learned her fibrolamellar carcinoma had spread to bone and blood, placing her at stage 4. She opted out of standard chemotherapy and agreed to join a trial for an off-the-shelf cancer vaccine designed for the tumor’s typical genetic abnormality. By September, five months post-treatment, she was declared in full remission and continues to be cancer-free.

Researchers note that unlike chemotherapy, such vaccines aim to teach the immune system to recognize and destroy cancer cells, potentially offering lasting protection. The success adds to recent advances, including Moderna’s personalized melanoma vaccine that recently cleared Phase 3 trials. Scientists stress that most vaccines remain experimental and are being tested in combination with other therapies to improve outcomes.